Yazar "Altintas, Derya Ufuk" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Effect of premedication on side effect frequency in patients to whom immunotherapy is applied
    (2019) Duyuler Aycin, Gulsah; Altintas, Derya Ufuk; Sasihuseyinoglu, Ayse Senay
    Aim: In this study, we aimed to investigate whether there are differences in terms of the frequency and severity of side effects in patients to whom premedication were given/or not before the application of subcutaneous allergen specific immunotherapy.Material and method: Patients receiving subcutaneous allergen-specific immunotherapy in our clinic between October 2014 and October 2015 were evaluated for side effects. In patients to whom subcutaneous allergen-specific immunotherapy was applied and reaction was occurred against this therapy; allergen type, reaction intensity and duration, and also use of premedication were recorded. When the patients were assessed in terms of side effects; edema and/or erythema from 2 to 5 cm, which were beginning within the first 24 hours in the injection site. That was defined as ‘local reaction’ and edema and/or erythema, if it was greater than 5 cm defined as ‘broad local reaction’.Results: Total of 101 patients, to whom allergen specific immunotherapy was applied, were included. In a year of the study; total of 660 injections were applied to 101 patients and reaction to injections were observed in 31 injections (4.6%). Reaction was observed in 20 individuals (19.8%). No significant difference was found between premedicated and non-premedicated groups in terms of the percentage of side effects and risk of side effects (p >0.59). Conclusion: In our study; patients with or without premedication were compared in terms of side effect frequency. In premedication group; ratio of local reaction was found to be low (20%). It was thought that premedication could reduce local reactions but did not prevent extensive local reaction. There was no difference when comparing the side effect frequency between the two groups. Keywords: Premedication; Immunotherapy; Side Effect.
  • Küçük Resim Yok
    Öğe
    Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
    (Wiley, 2024) Emiralioglu, Nagehan; Cakir, Banu; Sertcelik, Ahmet; Yalcin, Ebru; Kiper, Nural; Sen, Velat; Altintas, Derya Ufuk
    Background: The decline in pulmonary function is a predictor of disease progression in patients with cystic fibrosis (CF). This study aimed to determine the decline rate of percent predicted forced expiratory volume in 1 s (ppFEV1) based on the data of the CF Registry of Turkey. The secondary aim was to investigate the risk factors related to the decline in ppFEV1. Methods: A retrospective cohort study of CF patients over 6 years old, with pulmonary function data over at least 2 years of follow-up was extracted from the national CF registry for years 2017-2019. Patients were classified according to disease severity and age groups. Multivariate analysis was used to predict the decline in ppFEV1 and to investigate the associated risk factors. Results: A total of 1722 pulmonary function test results were available from 574 patients over the study period. Mean diagnostic age was older and weight for age, height for age, and body mass index z scores were significantly lower in the group of ppFEV1 < 40, while chronic Pseudomonas aeruginosa (p < .001) and mucoid P. aeruginosa colonization (p < .001) were significantly higher in this group (p < .001). Overall mean annual ppFEV1 decline was -0.97% (95% confidence interval [CI] = -0.02 to -1.92%). The mean change of ppFEV1 was significantly higher in the group with ppFEV1 >= 70 compared with the other (ppFEV1 < 40 and ppFEV1: 40-69) two groups (p = .004). Chronic P. aeruginosa colonization (odds ratio [OR] = 1.79 95% CI = 1.26-2.54; p = .01) and initial ppFEV1 >= 70 (OR = 2.98 95% CI = 1.06-8.36), p = .038) were associated with significant ppFEV1 decline in the whole cohort. Conclusions: This data analysis recommends close follow-up of patients with normal initial ppFEV1 levels at baseline; advocates for early interventions for P. aeruginosa; and underlines the importance of nutritional interventions to slow down lung disease progression.